Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Reedtz-Runge SL"'
Autor:
Bartholdy C; Novo Nordisk A/S, Copenhagen, Denmark., Reedtz-Runge SL; Novo Nordisk A/S, Copenhagen, Denmark., Wang J; Novo Nordisk A/S, Copenhagen, Denmark., Hjerrild Zeuthen L; Novo Nordisk A/S, Copenhagen, Denmark., Gruhler A; Novo Nordisk A/S, Copenhagen, Denmark., Gudme CN; Novo Nordisk A/S, Copenhagen, Denmark., Lamberth K; Novo Nordisk A/S, Copenhagen, Denmark.
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia [Haemophilia] 2018 Sep; Vol. 24 (5), pp. e354-e362. Date of Electronic Publication: 2018 Jul 19.
Autor:
Schultz HS; Immunogenicity Prediction and Tolerance, Global Research, Novo Nordisk A/S, Måløv, Denmark., Reedtz-Runge SL; NCD Project Management, Global Research, Novo Nordisk A/S, Måløv, Denmark., Bäckström BT; Immunogenicity Prediction and Tolerance, Global Research, Novo Nordisk A/S, Måløv, Denmark., Lamberth K; Immunogenicity Prediction and Tolerance, Global Research, Novo Nordisk A/S, Måløv, Denmark., Pedersen CR; Immunogenicity Assessment, Global Research, Novo Nordisk A/S, Måløv, Denmark., Kvarnhammar AM; Immunogenicity Prediction and Tolerance, Global Research, Novo Nordisk A/S, Måløv, Denmark.
Publikováno v:
PloS one [PLoS One] 2017 May 31; Vol. 12 (5), pp. e0178544. Date of Electronic Publication: 2017 May 31 (Print Publication: 2017).
Autor:
Lamberth K; Global Research, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark. zuben.sauna@fda.hhs.gov kplm@novonordisk.com., Reedtz-Runge SL; Global Research, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark., Simon J; Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapeutics, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA., Klementyeva K; Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapeutics, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA., Pandey GS; Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapeutics, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA., Padkjær SB; Global Research, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark., Pascal V; Global Research, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark., León IR; Global Research, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark., Gudme CN; Global Research, Novo Nordisk A/S, Novo Nordisk Park, DK-2760 Måløv, Denmark., Buus S; Laboratory of Experimental Immunology, Faculty of Health Sciences, University of Copenhagen, DK-2200 Copenhagen, Denmark., Sauna ZE; Hemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapeutics, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA. zuben.sauna@fda.hhs.gov kplm@novonordisk.com.
Publikováno v:
Science translational medicine [Sci Transl Med] 2017 Jan 11; Vol. 9 (372).